

## STEP THERAPY POLICY

- POLICY:** Antidepressants – Serotonin and Norepinephrine Reuptake Inhibitors Step Therapy Policy
- Cymbalta® (duloxetine HCl delayed-release capsules – Lilly, generic)
  - Desvenlafaxine extended-release tablets (Alembic /Ranbaxy [brand product])
  - Drizalma Sprinkle™ (duloxetine delayed-release capsules – Sun Pharma)
  - Effexor® XR (venlafaxine HCl extended-release capsules – Wyeth, generic)
  - Fetzima® (levomilnacipran HCl extended-release capsules – Forest)
  - Pristiq® (desvenlafaxine succinate extended-release tablets – Wyeth, generic)
  - Savella® (milnacipran HCl tablets – Forest)
  - Venlafaxine besylate extended-release tablets (Almatica)
  - Venlafaxine HCl tablets (generic only)
  - Venlafaxine HCl extended-release tablets (generic)

**REVIEW DATE:** 03/13/2024

---

### OVERVIEW

Desvenlafaxine, duloxetine, Fetzima, and venlafaxine are serotonin and norepinephrine reuptake inhibitors (SNRIs) indicated for the **treatment of depression**.<sup>1-9</sup> In addition, venlafaxine is indicated for the treatment of generalized anxiety disorder (GAD), social anxiety disorder, and panic disorder. Duloxetine delayed-release capsules are indicated for the treatment of GAD, the management of neuropathic pain associated with diabetic peripheral neuropathy, the management of fibromyalgia, and the management of chronic musculoskeletal pain. Savella is only indicated for the management of fibromyalgia.<sup>10</sup> While Savella is approved outside the US for major depressive disorder (MDD), it is not in development for this or any other indication in the US.

A venlafaxine *hydrochloride* (HCl) extended-release tablet formulation and a venlafaxine *besylate* extended-release tablet are also available.<sup>5,6</sup> These formulations do not carry the same indications as the capsule formulation (Effexor XR, generic). Venlafaxine HCl extended-release tablets are indicated for MDD and social anxiety disorder.<sup>5</sup> Equal doses of venlafaxine HCl extended-release tablets are bioequivalent to venlafaxine extended-release *capsules* (Effexor XR, generic) when administered under fed conditions; however, these products are not AB-rated to each other. Venlafaxine besylate extended-release tablets are indicated for MDD and GAD, and they are only available in a 112.5 mg strength.<sup>6</sup> Venlafaxine besylate extended-release tablets cannot be used to initiate venlafaxine treatment, titrate by doses less than 112.5 mg, or taper treatment.

Similarly, in addition to desvenlafaxine *succinate* extended-release tablets (Pristiq, generic), branded Desvenlafaxine is available.<sup>4,8</sup> Desvenlafaxine and desvenlafaxine succinate are available in the same strength extended-release tablets, and share the same indication (treatment of MDD). Desvenlafaxine, Desvenlafaxine fumarate (discontinued), and desvenlafaxine succinate are not AB-rated to each other. However, efficacy studies conducted with desvenlafaxine succinate are cited in the Desvenlafaxine product information. Drizalma Sprinkle relied on clinical efficacy studies for Cymbalta for approval and has the same indications as Cymbalta with the exception of a fibromyalgia indication.<sup>1,9</sup>

The selective serotonin reuptake inhibitors (SSRIs) are a pharmacologic class of agents with antidepressant action and efficacy in the treatment of a wide range of mood and anxiety disorders that include obsessive compulsive disorder (OCD), panic disorder, social anxiety disorder (social phobia), posttraumatic stress disorder (PTSD), bulimia-nervosa, and GAD.<sup>11</sup> There are many off-label uses for the SSRIs and SNRIs in

03/13/2024

© 2024. All Rights Reserved.

This document is confidential and proprietary. Unauthorized use and distribution are prohibited.

a wide variety of psychiatric, as well as nonpsychiatric, conditions. Of note, some patients may have a primary disorder, such as depression, and a comorbid condition, such as anxiety or sleep disorder, which may or may not affect response or the ability to tolerate adverse events (AEs).

## INDICATIONS

All of the SNRIs (with the exception of Savella) are indicated for the treatment of MDD. Some of the SNRIs carry additional indications (Table 1). Table 2 provides the approved indications for the available SSRIs.

### **Table 1. FDA-Approved Indications for the SNRIs in Adults.<sup>1-10</sup>**

SNRI – Serotonin norepinephrine reuptake inhibitor; MDD – Major depressive disorder; GAD – Generalized anxiety disorder; SAD – Social Anxiety Disorder; DPN – Diabetic peripheral neuropathy; ^ Efficacy studied in patients  $\geq 7$  years of age with GAD; \* Approved for use in patients  $\geq 13$  years of age; HCl – Hydrochloride.

### **Table 2. FDA-Approved Indications for the SSRIs.<sup>12-24</sup>**

**Table 2 (continued). FDA-Approved Indications for the SSRIs.**<sup>12-24</sup>

MDD – Major Depressive Disorder; OCD – Obsessive compulsive disorder; PTSD – Posttraumatic stress disorder; SAD – Social anxiety disorder; GAD – Generalized anxiety disorder; PMDD – Premenstrual dysphoric disorder; VMS – Vasomotor symptoms; \* Approved for the prevention of relapse during the continuation treatment phase of depression; † FDA-approved indication includes children and adolescents; ‡ FDA-approved indication includes adolescents 12 to 17 years of age; ^ FDA-approved indication includes children and adolescents 7 to 17 years of age; CR – Controlled release; HCl – Hydrochloride.

## POLICY STATEMENT

This program has been developed to encourage the use of a Step 1 Product prior to the use of a Step 2 Product. If the Step Therapy rule is not met for a Step 2 Product at the point of service, coverage will be determined by the Step Therapy criteria below. All approvals are provided for 1 year in duration.

**Automation:** A patient with a of one Step 1 Product within the 130-day look-back period is excluded from Step Therapy. Patients > 18 years of age are targeted in this Step Therapy program.

**Step 1:** citalopram tablets (Celexa, generic), generic citalopram oral solution, generic duloxetine delayed-release 20 mg, 30 mg, 60 mg capsules, escitalopram tablets (Lexapro, generic), escitalopram oral solution (Lexapro, generic), fluoxetine immediate-release capsules and tablets (Prozac, Sarafem, generic), generic fluoxetine oral solution, generic fluoxetine delayed-release capsules, generic fluvoxamine immediate-release tablets, generic fluvoxamine extended-release capsules, paroxetine HCl immediate- and controlled-release tablets (Paxil, Paxil CR, generic), paroxetine oral suspension (Paxil, generic), Pexeva, sertraline tablets (Zoloft, generic), sertraline oral solution (Zoloft, generic), Trintellix (formerly Brintellix), Viibryd, generic venlafaxine immediate-release tablets, generic venlafaxine extended-release capsules

**Step 2:** Cymbalta, Desvenlafaxine extended-release tablets (brand product), Drizalma Sprinkle, Effexor XR, Fetzima, Pristiq, Savella, generic desvenlafaxine succinate extended-release tablets, generic duloxetine 40 mg delayed-release capsules, generic venlafaxine HCl extended-release tablets, venlafaxine besylate extended-release tablets

## CRITERIA

1. If the patient has tried one Step 1 Product, approve a Step 2 Product.
2. If the patient is currently taking or has taken brand name Desvenlafaxine extended-release tablets, desvenlafaxine succinate extended-release tablets (Pristiq or generics), or Fetzima at any time in the past and discontinued its use, approve the Product that they have used.
3. If the patient has suicidal ideation, approve Desvenlafaxine extended-release tablets, desvenlafaxine succinate extended-release tablets (Pristiq or generics), or Fetzima.

## REFERENCES

1. Cymbalta<sup>®</sup> capsules [prescribing information]. Indianapolis, IN: Lilly; August 2023.
2. Effexor XR<sup>®</sup> extended-release capsules [prescribing information]. Morgantown, WV: Viartis; August 2023.
3. Venlafaxine hydrochloride tablets [prescribing information]. Parsippany, NJ: Teva; August 2023.
4. Pristiq<sup>®</sup> extended-release tablets [prescribing information]. Philadelphia, PA: Wyeth; August 2023.
5. Venlafaxine extended-release tablets [prescribing information]. Cranbury, NJ: Sun; September 2023.
6. Venlafaxine besylate extended-release tablets [prescribing information]. Morristown, NJ: Almatica; August 2023.
7. Fetzima<sup>®</sup> extended-release capsules [prescribing information]. North Chicago, IL: AbbVie; August 2023.
8. Desvenlafaxine extended-release tablets [prescribing information]. Cranbury, NJ: Sun; August 2023.

9. Drizalma Sprinkle™ delayed-release capsules [prescribing information]. Cranbury, NJ: Sun; August 2023.
10. Savella® tablets [prescribing information]. Madison, NJ: Allergan; August 2023.
11. Facts and Comparisons® eAnswers. Wolters Kluwer UpToDate, Inc.; 2024. Available at: <http://fco.factsandcomparisons.com/lco/action/home>. Accessed on March 11, 2024. Search terms: SSRIs, SNRIs.
12. Prozac® capsules [prescribing information]. Indianapolis, IN: Lilly; August 2023.
13. Paxil® tablets and oral suspension [prescribing information]. Weston, FL: Apotex; August 2023.
14. Zoloft® tablets, oral concentrate [prescribing information]. New York, NY: Pfizer; August 2023.
15. Celexa® tablets and oral solution [prescribing information]. Irvine, CA: Allergan; August 2023.
16. Paxil CR® controlled-release tablets [prescribing information]. Westin, FL: Apotex; February 2024.
17. Lexapro® tablets and oral solution [prescribing information]. Irvine, CA: Allergan; August 2023.
18. Pexeva® tablets [prescribing information]. Roswell, GA: Sebela; August 2023.
19. Fluvoxamine maleate tablets [prescribing information]. Baudette, MN: ANI; August 2023.
20. Sarafem® capsules [prescribing information]. Indianapolis, IN: Lilly; August 2023.
21. Fluvoxamine extended-release capsules [prescribing information]. Chestnut Ridge, NY: Par; October 2023.
22. Viibryd® tablets [prescribing information]. Madison, NJ: Allergan; August 2023.
23. Trintellix™ (formerly Brintellix® tablets) [prescribing information]. Lexington, MA and Deerfield, IL: Takeda and Lundbeck; August 2023.
24. Brisdelle® capsules [prescribing information]. Roswell, GA: Sebela; August 2023.